BeOne Medicines AG share price today

BeOne Medicines AG's share price was $376.66 at the close on 4 November 2026. It has been rising for 16 weeks. That is 15.8% above its average price over the last 200 trading days. In the last 52 weeks it traded between $264 and $378, and at that close it sat 99% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today BeOne Medicines AG is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 16 weeks in a row.

Over the last 10 years the share price moved +1,191% while the S&P 500 moved +261%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

BeOne Medicines AG pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

BeOne Medicines AG is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

BeOne Medicines AG earned $237 M of net profit in the Jun 2026 quarter, +151.3% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY25 profit was $287 M. That is 13.9% of the quarter's revenue. The same quarter a year earlier earned $94.3 M.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

5 of the last 12 reported quarters were loss-making.

BeOne Medicines AG reported $1.7 B of revenue in the Jun 2026 quarter, +29.6% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 46.0% a year on average. The last full year, FY25, came in at $5.3 B.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to $6.1 B.

FY25 revenue was $5.3 B, +40.2% on the year before.

Recent pace: the last four quarters grew +34.7% on average, against 46.0% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +34.3%, against +41.9% a year over the last 8 quarters (rolling over).

BeOne Medicines AG's operating margin was 19.1% in the Jun 2026 quarter, 12.4 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between −126.4% and 8.4%. The latest quarter is above every full year in that period.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Across 5 years it has been between −126.4% and 8.4%, and FY25's 8.4% is the highest of them.

Why the margin moved: operating margin changed +12.4 percentage points on the year while gross margin changed +2.3 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead.

BeOne Medicines AG's cash-flow history is too short to judge how much of its profit turns into cash. In FY25 it brought in $1.1 B of operating cash against $287 M of profit. After $186 M of spending on assets, $942 M was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

BeOne Medicines AG does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $1.2 B on assets over the last 3 years. Averaged over those years that is 7.7% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $1.2 B over the last 3 years.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

BeOne Medicines AG's P/E is 67.4×, in the middle of its own history: higher than 40% of past readings. Its usual P/E (the middle reading) is 72.3×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks.

In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple.

BeOne Medicines AG's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

BeOne Medicines AG earned a ROE of 7% in FY25. That is up from a low of −46% in FY22. Its return on capital used (ROIC) is 26.0 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 5.4% net margin and 0.65× asset turnover (sales divided by assets).

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

Why the return is what it is (FY25): a 5.4% net margin × 0.65× asset turnover × 1.88× leverage (assets divided by equity) ≈ 6.6% on equity. The margin does its share; borrowing is a big part of it.

The key test, return on capital used minus the cost of capital: 33.6% − 7.6% = +26.0 percentage points. The 7.6% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value.

The 33.6% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 17.1%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

BeOne Medicines AG has total debt of $2.0 B against shareholder equity of $5.2 B as of Jun 2026, so its debt is 0.40× its equity. Year by year, that ratio went from 0.11 in FY21 to 0.46 in FY25. Keep that borrowing in mind when reading the returns on this page.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

We have no ownership or short-position figures for BeOne Medicines AG, so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 4.7 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

For BeOne Medicines AG, the Z-score is 5.65. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of 5.65 is well clear of the danger zone, so the balance sheet is not the risk here.

54.9 out of 100, rank 10 of 30 in Biotechnology, with 64% of the evidence available.

BeOne Medicines AG scores 54.9 out of 100 against the 30 companies it is compared with in Biotechnology, ranking 10. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.

The four parts add up to the total exactly: 22.3 + 13.4 + 9.1 + 10.1 = 54.9. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

BeOne Medicines AG ranks 10 of 30 Biotechnology companies on the 4-Factor Sector Score, with 54.9 out of 100.